Navigation

Novartis announces major United States deal

The Novartis pharmaceutical group says it will buy the Genoptix specialised cancer laboratory in the American state of California for $470 million (SFr452 million).

This content was published on January 24, 2011 - 11:22
swissinfo.ch and agencies

A statement from Basel-based Novartis on Monday said the acquisition would strengthen its diagnostics operations and diversify its operations further.










The Genoptix board is recommending shareholders accept an offer of $25 per share, which represents a premium of 27 per cent over Friday’s closing price.

Novartis said Genoptix, which specialises in diagnosing cancers in bone marrow, blood and lymph nodes, had sales of $184 million in 2009, employed a staff of 500 and was profitable.

The Swiss group last year bought the Texas-based Alcon eye care company for about $52 billion, including the shares held by the Nestlé food company.

This article was automatically imported from our old content management system. If you see any display errors, please let us know: community-feedback@swissinfo.ch

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

Share this story

Change your password

Do you really want to delete your profile?